Jaime Shaw
Family · Altoona, PANPI 1346974649
Payments from drug & device makers
Across 145 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$519
- Lilly USA, LLC$428
- GSK$408
- AbbVie$348
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$154
- Pfizer$102
- plus $455 from 15 others
What the payments were for
- Food & beverage$2,415100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 32 | $519 |
| Lilly USA, LLC | 26 | $428 |
| GSK | 27 | $408 |
| AbbVie | 19 | $348 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $154 |
| Pfizer | 6 | $102 |
| AstraZeneca | 4 | $68 |
| Amgen | 3 | $53 |
| Boehringer Ingelheim | 3 | $51 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Novartis | 2 | $41 |
| Cequr Corporation | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Biogen | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| Exact Sciences | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$100
How this compares
$2,415 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $70,866 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $29,726 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $959 |
| Levothyroxine Sodium | 69 | $640 |
| Atorvastatin Calcium | 33 | $454 |
| Gabapentin | 29 | $393 |
| Metformin Hcl | 38 | $373 |
| Pantoprazole Sodium | 31 | $363 |
| Hydroxyzine Hcl | 17 | $344 |
| Lisinopril | 39 | $340 |
| Levetiracetam | 15 | $335 |
| Bupropion Hcl SrBupropion Hcl | 20 | $324 |
| Potassium Chloride | 22 | $305 |
| Escitalopram Oxalate | 34 | $274 |
| Tamsulosin Hcl | 22 | $267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $519 | $70,86664 claims |
| GSKTrelegy Ellipta | $408 | $29,72646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.
Other family in Altoona
- Danielle GibbonsAltoona$29K
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.